Thrombotic Thrombocytopenic Purpura Pipeline

Involved pharmaceutical companies in the Thrombotic Thrombocytopenic Purpura market are Takeda, Lee’s Pharmaceutical and others.

DelveInsight’s Thrombotic Thrombocytopenic Purpura Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. This report gives a detailed clinical and non-clinical stage products analysis. The TTP report also highlights the unmet needs with respect to the development of Thrombotic Thrombocytopenic Purpura. 

Some of the key highlights from the Thrombotic Thrombocytopenic Purpura Pipeline Report-

  • Apadamtase alfa: TAK-755 is the first and only ADAMTS13 replacement therapy currently in development for both types of TTP. TAK-755 can possibly be a groundbreaking treatment for thrombotic thrombocytopenic purpura, an uncommon and perilous thickening issue characterized by low or missing circling ADAMTS13 action.
  • The Apadamtase alfa (Takeda) drug has received an orphan designation for Thrombotic Thrombocytopenic Purpura from the US FDA.
  • Key companies involved in the Thrombotic Thrombocytopenic Purpura Pipeline are Takeda, Lee’s Pharmaceutical

Request for Sample @ Thrombotic Thrombocytopenic Purpura Pipeline Insight

Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anaemia, severe thrombocytopenia, and organ ischemia with profound thrombocytopenia. TTP is characterized by a severe deficiency in ADAMTS13 (a disintegrin & metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor (vWf)-cleaving protease.

Thrombotic Thrombocytopenic Purpura Pipeline Emerging Therapies: Drug Profile

  •         BAX 930: Takeda

BAX 930/ TAK755/SHP655 (Shire) is a fully glycosylated recombinant human ADAMTS-13 protein that restores the missing enzyme in a patient’s blood without the risk for complications for human-donor plasma. 

The FDA has been granted fast track designation to BAX930 for the therapy of acute episodes of hereditary TTP in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.

Currently, the drug is in phase III trial, which aims to assess the safety & efficacy of BAX 930 in the prevention & treatment of acute episodes of thrombotic thrombocytopenic purpura in participants with severe congenital deficiency of ADAMTS13.

  •         Anfibatide: Lee’s Pharmaceutical

Anfibatide (Lee’s Pharmaceutical) is a snake venom-derived protein that acts as a platelet glycoprotein Ib antagonist. It is in Phase II studies being evaluated as adjuvant therapy for plasma exchange in patients with acquired TTP. The drug has received an orphan designation for TTP from the US FDA.

Know More Information @ Thrombotic Thrombocytopenic Purpura Pipeline Drugs

Key Pipeline Therapies along with Companies 

  • Apadamtase alfa: Takeda
  • Anfibatide: Lee’s Pharmaceutical
  • HB-adMSCs: Hope Biosciences

Thrombotic Thrombocytopenic Purpura Therapeutic Assessment

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Intravenous
  • Inhalation
  • Oral
  • Subcutaneous 

By Molecule Type 

  • Small Molecule 
  • Gene Therapy
  • Stem Cell Therapy

By Mechanism of Action

  • Protease Inhibitors
  • Immunomodulatory

By Targets

  • Protease 
  • Immune System

By Stage and Route of Administration

By Stage and Product Type

Contact here for more information @ Thrombotic Thrombocytopenic Purpura Pipeline Assessment

Scope of the Report

  • Coverage- Global
  • Key Market Players- Takeda, Lee’s Pharmaceutical and Hope Biosciences and others
  • Key Thrombotic Thrombocytopenic Purpura Pipeline Therapies- Apadamtase alfa, Anfibatide, HB-adMSCs and others

Table of content

1 Report Introduction
2 Thrombotic Thrombocytopenic Purpura
3 Thrombotic Thrombocytopenic Purpura Current Treatment Patterns
4 Thrombotic Thrombocytopenic Purpura DelveInsight’s Analytical Perspective
5 Therapeutic Assessment
6 TTP Late Stage Products (Phase-III)
7 TTP mid Stage Products (Phase-II)
8 Thrombotic Thrombocytopenic Purpura Early Stage Products (Phase-I)
9 Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 TTP Discontinued Products
13 TTP Product Profiles
14 Thrombotic Thrombocytopenic Purpura Key Companies
15 TTP Key Products
16 Dormant and Discontinued Products
17 Thrombotic Thrombocytopenic Purpura Unmet Needs
18 Thrombotic Thrombocytopenic Purpura Future Perspectives
19 Thrombotic Thrombocytopenic Purpura Analyst Review
20 Appendix
21 Report Methodology

Know more of what’s covered in the Thrombotic Thrombocytopenic Purpura Pipeline Assessment report

Key Questions Answered in the Thrombotic Thrombocytopenic Purpura report

  • What are the current choices for TTP treatment? 
  • How many key players are developing therapies for the treatment of TTP
  • What is the principal treatment developed by these pharma key players in the sector?
  • How many treatments are developed by each company for the treatment of TTP?
  • How many TTP emerging therapies are in the early-stage, mid-stage, and late stage of development for the treatment of Thrombotic Thrombocytopenic Purpura?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers & acquisitions, and major licensing activities that will impact the Thrombotic Thrombocytopenic Purpura market?
  • Which are the dormant & discontinued products & the causes for the identic?
  • What is the unmet necessity for current therapies for the treatment of Thrombotic Thrombocytopenic Purpura?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Thrombotic Thrombocytopenic Purpura therapies? 
  • What are the clinical studies going on for Thrombotic Thrombocytopenic Purpura and their status?
  • What are the consequences of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Thrombotic Thrombocytopenic Purpura
  • How many patents are granted & pending for the emerging therapies for the treatment of Thrombotic Thrombocytopenic Purpura

Request for a Webex demo @ Thrombotic Thrombocytopenic Purpura Pipeline and get a walk-through of our report

Related Reports

Thrombotic Thrombocytopenic Purpura Market

DelveInsight’s Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology and Market Forecast 2030 report.

Thrombotic Thrombocytopenic Purpura Epidemiology

DelveInsight’s Thrombotic Thrombocytopenic Purpura – Epidemiology Forecast 2030 report

Thrombotic Thrombocytopenic Purpura Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Thrombotic Thrombocytopenic Purpura Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020″ report 

Beta-thalassemia Market

DelveInsight’ s Beta-thalassemia Market Insights, Epidemiology and Market Forecast – 2030 report.

Hemophilia B Market

DelveInsight’ s Hemophilia B – Market Insights, Epidemiology and Market Forecast – 2030 report.

Hemophilia Market

DelveInsight’ s Hemophilia – Market Insights, Epidemiology and Market Forecast – 2030 report.

Hypofibrinogenemia Market 

Hypofibrinogenemia Market Insights, Epidemiology, & Market Forecast-2030 report

Visit on our blog section-

About DelveInsight

DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.